CagriSema

CagriSema is an investigational combination therapy consisting of two complementary peptide compounds: Cagrilintide, a long-acting amylin analogue, and Semaglutide, a GLP-1 receptor agonist.

This combination has attracted significant scientific interest due to its dual approach to metabolic regulation, appetite signalling and body-weight management. Researchers investigate how these two compounds interact with different hormonal pathways involved in satiety, food intake, glucose regulation and energy balance.

CagriSema represents an important area of research within metabolic science, particularly in studies exploring the combined effects of amylin and GLP-1 receptor activation.

Key Features

✓ Combines amylin analogue and GLP-1 receptor agonist research
✓ Investigated for dual metabolic signalling pathways
✓ Studied in appetite regulation and satiety models
✓ Explored in glucose metabolism research
✓ Investigated in body-weight regulation studies
✓ Relevant to obesity and metabolic health research

Dual Receptor Research

CagriSema combines two compounds that act through different but complementary hormonal pathways.

Cagrilintide targets amylin and calcitonin receptor complexes, while Semaglutide activates GLP-1 receptors. Researchers investigate how these pathways interact to influence appetite regulation, metabolic signalling and energy balance.

Appetite Regulation Research

Research explores the combined effects of amylin and GLP-1 signalling on hunger mechanisms, food intake and satiety.

Both pathways are involved in physiological processes that influence appetite and the regulation of energy consumption.

Glucose Metabolism Research

Semaglutide’s interaction with GLP-1 receptors has made it an important subject of glucose metabolism research. CagriSema provides an opportunity to investigate the relationship between GLP-1 and amylin signalling in metabolic regulation.

Energy Balance & Body-Weight Research

Researchers investigate the potential complementary effects of these two compounds in laboratory and clinical research models examining energy balance, food intake and body-weight regulation.

Scientific Research Context

Metabolic regulation involves a complex network of hormonal pathways responsible for controlling appetite, glucose levels and energy utilisation.

CagriSema combines two established areas of metabolic research:

Cagrilintide

• Long-acting synthetic amylin analogue
• Investigated for amylin receptor signalling
• Studied in appetite and satiety regulation
• Explored in gastric emptying research

Semaglutide

• GLP-1 receptor agonist
• Investigated in glucose regulation
• Studied in appetite and food intake mechanisms
• Explored in metabolic and energy balance research

The combination allows researchers to investigate:

• Dual amylin and GLP-1 receptor signalling
• Appetite and hunger regulation
• Satiety mechanisms
• Glucose metabolism
• Gastric emptying physiology
• Energy balance regulation
• Obesity-related metabolic pathways
• Combined hormonal signalling mechanisms

Common Research Applications

CagriSema is investigated in research programmes involving:

• GLP-1 receptor activation
• Amylin receptor signalling
• Appetite regulation mechanisms
• Satiety and food intake research
• Glucose metabolism
• Gastric emptying studies
• Energy balance and body-weight regulation
• Obesity and metabolic health research

Related Research Compounds

Researchers investigating metabolic regulation and appetite signalling may also study:

• Cagrilintide – amylin receptor signalling and appetite regulation research.
• Semaglutide – GLP-1 receptor signalling and glucose metabolism research.
• Tirzepatide – dual GIP and GLP-1 receptor signalling research.
• Retatrutide – multi-receptor metabolic signalling research.
• MOTS-C – mitochondrial signalling and metabolic adaptation research.

These compounds are investigated through different mechanisms within metabolic science and obesity-related research.

Product Specifications

Product Name: CagriSema
Compound Type: Combination Peptide Therapy
Research Category: Metabolic & Appetite Regulation Research
Active Components: Cagrilintide and Semaglutide
Primary Targets: Amylin/Calcitonin Receptor Complexes and GLP-1 Receptors
Physical Form: Research Grade Powder
Available Sizes: 10mg, 20mg and 30mg Vials
Application: Scientific Research Use Only

Important Notice

For laboratory research use only. This product description is intended solely for research, analytical and educational purposes. It is not intended for human or animal consumption, weight-loss treatment, therapeutic use, veterinary use, diagnostic procedures or administration of any kind.